Table 3.

Overview of the studies investigating subthreshold micropulse laser treatment for macular edema after branch retinal vein occlusion

Authors	Year	Eyes	Inclusion criteria	Laser type and parameters	Study design
Parodi et al. [56]	2015	35 eyes Group 1: SML: n = 18 Group 2: IVT Bevacizumab (PRN after 3 initial injections) n = 17	ME to due BRVO CFT > 250 µm Without non-perfusion ≥ 5 disc areas All eyes were previously treated with conventional grid laser	Iris Medical OcuLight SLX 810 nm, Ø 125 µm, 15% DC, 0.3 s, power: titration	Prospective, randomized, interventional
Inagaki et al. [57]	2014	32 eyes Group 1: BCVA ≤20/40 n = 15 Group 2: BCVA >20/40 n = 17	ME due to BRVO (ischemic/non-ischemic) CRT <600 µm No prior macular therapy (LC, IVT etc.) within last 6 months	Iris Medical OcuLight SLX, 810 nm, Ø 200 µm, 15% DC, 0.2 or 0.3 s, Power: 750–1500 mW (90%) for 0.2 s or 360–2000 mW (60%) for 0.3 s	Retrospective, single-center, nonrandomized, interventional case series
Parodi et al. [58]	2008	24 eyes Group 1: SML only n = 13 Group 2: SML + IVT Triamcinolone n = 11	ME due to BRVO CRT >212 µm No prior laser treatment Without non-perfusion ≥5 disc areas	Iris Medical OcuLight SLX, 810 nm Ø 125 µm 15% DC, 0.3 s Power: titration	Prospective randomized pilot clinical trial
Parodi et al. [59]	2006	36 eyes Group 1: SML grid n = 17 Group 2: Krypton grid n = 19	ME due to BRVO CRT >210 µm No prior laser treatment Without non-perfusion ≥5 disc areas	Iris Medical OcuLight SLX 810 nm Ø 125 µm, 10% DC, 0.2 s, power: titration Novus Omni Krypton Ø 100 µm, 0.1 s	Prospective, randomized clinical trial

Authors	FU (months)	Central retinal thickness	Best corrected visual acuity	Safety	Additional treatments
Parodi et al. [56]	12	SML group (CFT): BL: 485.5 µm 3 months: 472.0 µm 6 months: 475.0 µm 9 months: 475.0 µm 12 months: 445.0 µm IVT group (CFT): BL: 484.2 µm 3 months: 305.0 µm 6 months: 266.0 µm 9 months: 265.0 µm 12 months: 271.0 µm IVT group significantly better (p = 0.001)	SML group: BL: 0.92 logMAR 3 months: 0.89 logMAR 6 months: 0.89 logMAR 9 months: 0.94 logMAR 12 months: 0.99 logMAR IVT group: BL: 0.94 logMAR 3 months: 0.88 logMAR 6 months: 0.88 logMAR 9 months: 0.85 logMAR 12 months: 0.72 logMAR IVT group significantly better (p = 0.0085)	No laser scars	Not mentioned
Inagaki et al. [57]	12	Group 1: (BCVA ≤20/40 Snellen) BL: 409.3 µm 1 month: 394.3 µm 3 months: 371.3 µm 6 months: 313.5 µm 12 months: 303.5 µm Group 2: (BCVA >20/40 Snellen) BL : 373.3 µm 1 month: 353.5 µm 3 months: 313.1 µm 6 months: 294.1 µm 12 months: 320.1 µm Significant CRT decrease at 3, 6, and 12 months for both groups. No significant difference between the groups at any time point	Group 1: (BCVA ≤ 20/40 Snellen) BL: 0.59 logMAR 1 month: 0.54 logMAR 3 months: 0.54 logMAR 6 months: 0.58 logMAR 12 months: 0.51 logMAR Group 2: (BCVA >20/40 Snellen) BL: 0.13 logMAR 1 month: 0.09 logMAR 3 months: 0.13 logMAR 6 months: 0.09 logMAR 12 months: 0.12 logMAR	No laser scars	Group 1: n = 8 (53.3%) Group 2: n = 3 (17.6%)
Parodi et al. [58]	12	SML only: BL: 429 µm 3 months: 364 µm 6 months: 320 µm 9 months: 290 µm 12 months: 278 µm SML + IVT (triamcinolone): BL: 476 µm 3 months: 269 µm 6 months: 276 µm 9 months: 260 µm 12 months: 283 µm Combined SML + IVT showed better response at 3 months (p < 0.001). No difference between groups from 9th month on	SML only: BL: 0.76 logMAR 3 month: 0.78 logMAR 6 months: 0.78 logMAR 9 months: 0.73 logMAR 12 months: 0.65 logMAR SML + IVT (triamcinolone): BL: 0.67 logMAR 3 months: 0.50 logMAR 6 months: 0.45 logMAR 9 months: 0.36 logMAR 12 months: 0.35 logMAR Combined SML + IVT showed significant better response at 9th and 12th months (p < 0.009, p = 0.011, respectively)	No Laser scars	Not mentioned
Parodi et al. [59]	24	SML grid: BL: 480 µm 6 months: 457 µm 12 months: 217 µm 18 months: 215 µm 24 months: 208 µm Krypton grid: BL: 454 µm 6 months: 252 µm 12 months: 226 µm 18 months: 229 µm 24 months: 217 µm Krypton showed better response at 3 months and 6 months (p < 0.001). SML showed better response from 12th month on (p < 0.001)	SML grid: BL: 0.70 logMAR 6 months: 0.70 logMAR 9 months: 0.55 logMAR 12 months: 0.51 logMAR 24 months: 0.49 logMAR Krypton grid: BL: 0.69 logMAR 6 months: 0.60 logMAR 9 months: 0.58 logMAR 12 months 0.57 logMAR 24 m: 0.56 logMAR No statistical difference between groups	No laser scars after SML	Not mentioned

BRVO branch retinal vein occlusion, BL baseline, CFT central foveal thickness, CRT central retinal thickness, DC duty cycle, FA fluorescein angiography, IVT intravitreal drug therapy, logMAR logarithm of the minimum angle of resolution, ME macular edema, PRN pro re nata, SML subthreshold micropulse laser